ArticleJournal of applied clinical medical physics2026
Electron spatially fractionated radiation therapy using a clinically biocompatible 3D-printed tungsten-filament GRID.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpatially fractionated radiation therapy (SFRT) can enhance tumor control by delivering high-dose subvolumes while sparing normal tissue and stimulating antitumor immunity. However, its application to superficial disease through electron beam radiation therapy remains limited. Electron SFRT (eSFRT) could serve as a strategy for initial tumor downsizing of ulcerated cutaneous and subcutaneous tumors by delivering a superficial, spatially heterogeneous dose, enabling subsequent conventional electron therapy to enhance local control. PURPOSE: To evaluate the dosimetric feasibility of eSFRT using a novel 3D-printed tungsten-filament GRID (TS) and compare it to lead sheet (LS) references.
methodsThe TS GRID collimators were 3D-printed from a tungsten alloy filament (91%-93% tungsten by weight, PLA-based), with a hexagonal array of 27 apertures (1.5 cm diameter, 2.0 cm spacing, 1 mm thickness) in a 10 × 10 cm
resultsThe TS GRID collimator produced highly heterogeneous superficial dose distributions with PVDR > 2.0 at depths > 10 mm for 6-9 MeV, supporting spatially fractionated dose delivery. PVDR reductions on curved phantom surfaces were minimal (<3%). TS demonstrated reproducible geometry, mechanical stability, and biocompatibility, enabling direct placement on superficial tumors. Compared to previously reported tungsten-based composite GRID collimators, including tungsten functional paper (TFP) and tungsten-containing rubber (TCR), TS achieved higher PVDR at clinically relevant depths. LS GRID collimators achieved slightly higher PVDR but are not suitable for clinical use directly on skin.
conclusionsThis study demonstrates the feasibility of eSFRT using a 3D-printed TS GRID collimator to deliver superficial, spatially heterogeneous doses. TS provides reproducible geometry, mechanical stability, and biocompatibility, making it a clinically translatable alternative to lead, TFP, and TCR GRID collimators warranting further preclinical and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.